Clinical Trial Update: Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity [Phase 2]

View source ↗

Summary

A Phase 2 trial of bevacizumab for retinopathy of prematurity reports results indicating suppression of pathological retinal angiogenesis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinopathy of Prematurity

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Retinopathy of Prematurity | Phase 2 | Status: UNKNOWN | Results posted: 2014-06-09